[Alpha 1-acid glycoprotein and carbamazepine].
Levels of alpha 1-acid glycoprotein (alpha 1-AGP) were determined in 40 epileptic patients who had been also treated with carbamazepine (CBZ) and, in some patients, phenobarbital (PB) for at least 3 months. alpha 1-AGP levels were also determined in 28 controls. CBZ dit not alter blood levels of alpha 1-AGP while CBZ-PB decreased them. Such results are at variance with recent studies which suggested an increase of alpha 1-AGP in epileptic patients treated either with phenytoin or phenytoin + PB, or + CBZ, or + primidone.
D000328:Adult; D002220:Carbamazepine / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D009961:Orosomucoid / Q000097:blood*; D010634:Phenobarbital / Q000627:therapeutic use
D009961:Orosomucoid; D002220:Carbamazepine; D010634:Phenobarbital
Alpha 1-glycoprotéine acide et carbamazépine.